Gene therapy against hemophilia

Hannover Medical School (MHH) is one of the first institutions in Germany to be authorized to carry out a new innovative treatment for haemophilia A and B

07-Oct-2024 - Cell and gene therapies are on the rise. This is a new glimmer of hope for people with previously untreatable or barely treatable diseases. Another new therapeutic method has now been added to the list: gene therapy for hemophilia, also known as bleeding disorder. The Hemophilia Center at ...

Animal-free cell therapy from Aachen secures global growth

PL BioScience closes Series A financing in the amount of 7.8 million euros

09-Aug-2024 - PL BioScience GmbH has successfully completed a Series A financing round. The growth financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep ...

Sharpening the gene scissors together

Max Delbrück Centre and biotech start-up AlgenScribe cooperate

29-Jul-2024 - The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. A special kind of ...

Captain T Cell secures seed financing round

Start-up develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies

28-May-2024 - Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic. Captain T Cell GmbH announced the successful ...

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million

"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

24-May-2024 - Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$600million (around €550million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's ...

Limula raises CHF 6.2 million to develop automated cell and gene therapy manufacturing platform

Award-winning technology combines a bioreactor and a centrifuge into one single vessel for the first time

23-May-2024 - Over the last decade, several breakthrough Cell and Gene Therapy products have been approved in the USA and Europe to turn stem cells and immune cells into ‘living cures’, bringing hope to millions living with life-threatening conditions. However, these treatments remain out of reach for 98% of ...

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

Expanding analytical service capabilities for life science companies developing advanced treatments for cancer and rare diseases

08-May-2024 - Solvias announced that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and ...

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

First regulatory T cell therapy from an unmatched third-party donor

26-Mar-2024 - ActiTrexx GmbH, a clinical-stage company focusing on the activation of regulatory T cells, has treated the first patient with Actileucel, its novel cell therapy for the prevention and treatment of Graft-versus-Host Disease (GvHD) in patients receiving an allogeneic haematopoietic stem cell ...

MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space

“MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in cell and gene therapy development and production”

28-Feb-2024 - MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP (~$9 million USD) Series A financing round, led by Mercia Ventures. Existing investor Calculus ...

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

14-Feb-2024 - BioNTech SE and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory ...